Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Alexandra Giraldo-Marín"'
Autor:
Carmen Beato Zambrano, Antonio Javier Jiménez López, Anna Librán Oriol, Gala Serrano Bermúdez, Oliver Higuera Gómez, Pilar Torres, Jose L. Perez, Almudena Sanz Yagüe, Alfredo Paredes Lario, Rodolfo Chicas Sett, Manuel Cobo Dols, Ibone Huerta González, María Isabel Blancas López-Barajas, Alexandra Giraldo Marín, Pedro Sánchez Mauriño, Luis Cabezón Gutiérrez, Diana Moreno Muñoz, Begoña Soler López, Ignacio Delgado Mingorance, Francisco Javier García Navalón
Publikováno v:
BMJ Supportive & Palliative Care
Dipòsit Digital de la UB
Universidad de Barcelona
Dipòsit Digital de la UB
Universidad de Barcelona
ObjectivesOpioid-induced constipation (OIC) can affect up to 63% of all patients with cancer. The objectives of this study were to assess quality of life as well as efficacy and safety of naloxegol, in patients with cancer with OIC.MethodsAn observat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e43bf8dbce96b36c670bd2937fdd1078
https://doi.org/10.1136/bmjspcare-2020-002249
https://doi.org/10.1136/bmjspcare-2020-002249
Autor:
Rodolfo Chicas-Sett, Gala Serrano Bermúdez, Anna Librán Oriol, Francisco Javier García Navalón, Oliver Higuera Gómez, Manuel Cobo Dols, Pedro Sánchez Mauriño, Alexandra Giraldo Marín, Pilar Torres, Ibone Huerta González, Almudena Sanz-Yagüe, Ignacio Delgado Mingorance, Jose L. Perez, Luis Cabezón-Gutiérrez, María Isabel Blancas López-Barajas, Carmen Beato Zambrano, Diana Moreno Muñoz, Begoña Soler López, Alfredo Paredes Lario
Publikováno v:
BMJ Supportive & Palliative Care. :bmjspcare-2020
ObjectivesNaloxegol is a peripherally acting µ-opioid receptor antagonist (PAMORA) for treatment of opioid-induced constipation (OIC). The main objective was to analyse the long-term efficacy, quality of life (QOL) and safety of naloxegol in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::455dd69107cbbde829c26cc23896866f
https://doi.org/10.1136/bmjspcare-2020-002816
https://doi.org/10.1136/bmjspcare-2020-002816
Autor:
Alexandra Giraldo-Marín, Oliver Higuera, Luis Cabezón-Gutiérrez, Almudena Sanz-Yagüe, Rodolfo Chicas Sett, Gala Serrano Bermúdez, Pilar Togores, Ignacio Delgado, Francisco Javier García Navalón, Carmen Beato, Pedro Sánchez Mauriño, Ibone Huerta-González, Antonio Javier Jiménez-López, Anna Librán-Oriol, Manuel Cobo Dols, Begoña Soler, Diana Moreno, Alfredo Paredes Lario, José-Luis Fírvida Pérez, Isabel Blancas
Publikováno v:
Journal of Clinical Oncology. 38:e24155-e24155
e24155 Background: Naloxegol is a peripherally acting, µ-opioid receptor antagonist for treatment of opioid-induced constipation (OIC). The main objective of this study was to analyze the efficacy and safety of naloxegol in patients with cancer in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbcdbf901d28fc1bb232015fb4397d05
https://doi.org/10.1200/jco.2020.38.15_suppl.e24155
https://doi.org/10.1200/jco.2020.38.15_suppl.e24155